Stephen Ertz, DPM
Podiatrist · Shreveport, LANPI 1356321681
Payments from drug & device makers
What this record shows
This record is dominated by education: $1,115 of the $1,802 with a category attached, or 61.9%. Pylant Medical accounts for 61.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,239 and has fallen 91.4% since, to $106 in 2025. That places this record below the midpoint for podiatrist clinicians in LA, where the typical reported total is $2,398.
Across 29 payments — averaging $62.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$1K
- Organogenesis Inc.$187
- Convatec Inc.$159
- Medtronic$158
- Smith+Nephew$124
- Paratek Pharmaceuticals, Inc.$43
- plus $16 from 1 others
What the payments were for
- Food & beverage$68738%
- Education$1,11562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 1 | $1,115 |
| Organogenesis Inc. | 11 | $187 |
| Convatec Inc. | 9 | $159 |
| Medtronic | 3 | $158 |
| Smith+Nephew | 1 | $124 |
| Paratek Pharmaceuticals, Inc. | 3 | $43 |
| Biowound Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$134
- Santyl$124
- REGRANEX$124
- Oasis$124
How this compares
$1,802 in reported general payments places this provider in the 45th percentile of 68 podiatrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 12 | $252 |
| Mupirocin | 17 | $127 |
| Gabapentin | 14 | $104 |
| Terbinafine Hcl | 15 | $71 |
| Oxaprozin | 11 | $47 |
| Prednisone | 18 | $22 |
| Meloxicam | 24 | $22 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Shreveport
- Bryan RandolphShreveport$5K
- Jerry ToupsShreveport$4K
- Angelo MorrealeShreveport$2K
- Cassell HudsonShreveport$466
- Alaye WhyteShreveport$124
- Maxime SavardKenner$74K
- David TranMonroe$24K
- Tyler TewilliagerHouma$16K
- Rustin AjdariSlidell$15K
- Oghale EleyaeNatchitoches$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.